Sponsors (7)
The bill aims to expand patient access and lower costs by making many biosimilars easier to substitute and by streamlining review, but it does so by reducing some data and statutory safeguards—creating trade-offs between near-term affordability/access and regulatory certainty, prescriber confidence, and longer-term innovation incentives.
Patients with chronic conditions (including Medicare and Medicaid beneficiaries) will have broader access and likely lower out-of-pocket costs because many 351(k) biosimilars would be automatically deemed interchangeable, enabling pharmacy-level substitution without additional approvals.
Biologics developers, hospitals, and patients may see faster and cheaper biosimilar entry because clarified application requirements and limits on additional FDA data requests streamline review and reduce development costs, encouraging more biosimilar competitors.
Small biologic manufacturers with existing unexpired first interchangeable exclusivity retain their awarded protection periods, preserving expected market protections and investment returns for those developers.
Patients with chronic conditions (including Medicare and Medicaid beneficiaries) could face increased safety or efficacy risks because automatically deeming many biosimilars interchangeable may reduce the amount of direct interchangeability evidence for some products before substitution.
Hospitals, health systems, and patients may encounter reduced regulatory clarity and greater legal or substitution disputes because narrowing FDA guidance requirements and removing statutory interchangeability references can weaken oversight and operational guidance.
Prescribers and patients could lose confidence in switching decisions because reduced data requirements for licensure may weaken incentives for manufacturers to conduct comparative switching studies that inform clinical practice.
Based on analysis of 2 sections of legislative text.
Revises FDA biosimilar application rules and deems many biosimilars 'interchangeable' after a 60‑day transition while protecting certain existing exclusivities.
Introduced September 19, 2025 by August Pfluger · Last progress September 19, 2025
Changes how FDA evaluates and labels biosimilar biological products and creates a 60-day transition after enactment that will render many biosimilars automatically “deemed interchangeable.” It reorganizes and clarifies application content and cross‑references in the law governing biosimilar licensing, preserves certain existing exclusivity rights that were already in effect, and removes or adjusts statutory references to the term “interchangeable.” The amendments are largely technical and legal: they revise the text and internal structure of the statute that governs biosimilar applications, require the Secretary to determine submitted information shows biosimilarity, establish automatic deemed‑interchangeable status for many products after the transition date while protecting some pre‑existing exclusivity periods, and make conforming changes across related statutes to reflect the new treatment of interchangeability.